The global Bronchitis Treatment Market was valued at around US$ 5.5 Bn at the end of 2021. The market is projected to register a 4.1% CAGR and top a valuation of US$ 8.5 Bn by 2032.
“Rising geriatric population worldwide and increasing patient pool with bronchitis and other respiratory disorders are variables expected to set the tone of bronchitis treatment market.”
A medical condition called bronchitis causes the bronchial tubes to become inflamed, which results in coughing, usually with mucus. Dyspnea (shortness of breath), a cough that produces mucus, wheezing while breathing, and chest pain are all signs of bronchitis.
Bronchitis risk factors include viral or bacterial infections, ;smoking, gastric reflux, and ;exposure to irritants at work such as ;dust, ;pollution, ;and others. Pneumonia is one of the most frequent side effects of bronchitis and often happens when the infection progresses deeper into the lungs. Thus, the fluid in the lungs' air sacs fills up due to this illness.
| Attributes | Details |
|---|---|
| Bronchitis Treatment Market Value in 2021 | US$ 5.5 Billion |
| Bronchitis Treatment Market Value in 2032 | US$ 8.5 Billion |
| Bronchitis Treatment Market CAGR (2022 to 2032) | 4.1% |
The aging ;population with a higher incidence of bronchitis, higher levels of toxic chemicals and pollutants, and exposure to dust in the workplace or environment are major factors propelling the growth of the ;market. Additionally, people with a history of bronchitis in their families may have it more frequently.
For instance, one of the main factors fueling the expansion of the market for bronchitis treatments is the rising prevalence of smoking. In the US, over 32,000 ;million people used cigarettes in 2020, according to the CDC.
Significant ;factors that can have a major impact on the revenue growth of the global bronchitis treatment market include government-led initiatives to increase treatment awareness and market penetration of the key players ;in developing economies. The treatment of COPD has advanced, including the use of small-cell therapy and combination medications. Additionally, nonpharmacological treatments have become more popular over time.
The bronchitis treatment market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
A huge chunk of the global market belongs to North America because of the region's developed healthcare infrastructure and the ;population's awareness of health issues.
Apart from North America, the European market is also anticipated to grow at a rapid pace, due to the rising prevalence of chronic bronchitis and increasing healthcare expenditure by European Commissions.
Furthermore, the Asia Pacific region is also expected to uplift the revenue of the bronchitis treatment market due to the high presence of pollutants in numerous developing economies in Asia which has led to extensive R&D activities in the region to reduce the morbidity of chronic bronchitis.
Melinta Therapeutics, AstraZeneca, Pfizer Inc., Abbot, GlaxoSmithKline Plc., Cadila Healthcare Limited., Sanofi SA., Novartis, Glenmark, Cipla Inc, Dr. Reddy's Laboratories Ltd., Boehringer Ingelheim Pharmaceuticals, Inc.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 4.1% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered | Type, Treatment, Drug Class, Distribution Channel, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel |
| Key Players | Melinta Therapeutics; AstraZeneca; Pfizer Inc.; Abbot; GlaxoSmithKline Plc.; Cadila Healthcare Limited.; Sanofi SA.; Novartis; Glenmark; Cipla Inc; Dr. Reddy's Laboratories Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc. |
| Customization | Available Upon Request |
The market is likely to register a CAGR of 4.1% through 2032.
The market is currently valued at US$ 3.83 Mn in 2022.
The market is likely to grow to a valuation of US$ 6.06 Mn by 2032.
North America is likely to be a leading market during the forecast period.
Explore Similar Insights
Bronchitis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
